MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
MediciNova, Inc.NASDAQ: MNOV
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $49.22K at the end of Q1 FY2026, up 0.4% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 49.22K USD
- Year-over-year change
- +0.4%
- 4-year CAGR
- +0.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.22K | +0.4% |
| FY2024 | 2024-12-31 | 49.05K | +0.0% |
| FY2023 | 2023-12-31 | 49.05K | +0.0% |
| FY2022 | 2022-12-31 | 49.05K | +0.0% |
| FY2021 | 2021-12-31 | 49.04K | — |
Common Stock vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's Mar 2026 common stock of $49.22K is the 3rd highest of the 11 companies compared; the peer median is $18.5K.
- Its year-over-year change of +0.4% is the 8th highest of 10, against a peer median of +22.6%.
- Common stock amounts to 0.1% of total assets for MNOV, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $276.9M | +0.2% | +1.2% | 198.0% | |
| Mar 2026 | $104.89K | +216.0% | +34.6% | 0.0% | |
| Mar 2026 | $49.22K | +0.4% | +0.1% | 0.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $38K | +22.6% | +12.1% | 0.0% |
| Mar 2026 | $33K | +10.0% | -33.7% | 0.0% | |
| Mar 2026 | $24K | +4.3% | +22.7% | 0.0% | |
CBUSCibus, Inc. | Mar 2026 | $13K | +44.4% | +150.9% | 0.0% |
| Mar 2026 | $11K | +37.5% | +31.0% | 0.0% | |
| Mar 2026 | $7K | +75.0% | +32.6% | 0.0% | |
| Mar 2026 | $6K | +0.0% | +18.6% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MNOV) | $18.5K | +22.6% | +22.7% | 0.0% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.43M | 18.51M | 51M | 40.36M | 30.81M |
| Short-term Investments | 0 | 39.98M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 174.94K | 714.54K | 184.83K |
| Total Current Assets | 72.01M | 58.99M | 51.17M | 41.07M | 30.99M |
| Property, Plant & Equipment (Net) | 881.78K | 674.76K | 621.21K | 382.41K | 192.57K |
| Goodwill | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M |
| Intangible Assets | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115.49K | 92.79K | 74.15K | 19K | 19K |
| Total Non-current Assets | 15.4M | 15.17M | 15.1M | 14.8M | 14.61M |
| Total Assets | 87.41M | 74.15M | 66.27M | 55.88M | 45.6M |
| Account Payables | 402.74K | 424.65K | 1M | 1.1M | 625K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 370.16K |
| Other Current Liabilities | 547.27K | 184.1K | 988.77K | 912.78K | 971.07K |
| Total Current Liabilities | 2.83M | 3.19M | 3.28M | 2.96M | 3.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 201.79K | 201.79K | 201.79K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 201.79K | 201.79K | 410.66K | 211.46K | 17.13K |
| Total Non-current Liabilities | 896.47K | 725.41K | 612.45K | 413.25K | 218.92K |
| Total Liabilities | 3.73M | 3.91M | 3.89M | 3.37M | 4.02M |
| Common Stock | 49.04K | 49.05K | 49.05K | 49.05K | 49.22K |
| Retained Earnings | (393.06M) | (407.13M) | (415.7M) | (426.75M) | (438.75M) |
| Accumulated OCI | (98.88K) | (115.28K) | (118.09K) | (135.15K) | (127.18K) |
| Other Stockholders Equity | (0) | (1) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 83.68M | 70.24M | 62.38M | 52.5M | 41.59M |
| Total Debt | 826.64K | 681.12K | 215.93K | 193.77K | 194.33K |
| Net Debt | (70.6M) | (17.82M) | (50.78M) | (40.17M) | (30.61M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.